Literature DB >> 21843631

New insights into autoantibody profiles from immune privileged sites in the eye: a glaucoma study.

Nils Boehm1, Dominik Wolters, Uta Thiel, Ulrike Lossbrand, Nelli Wiegel, Norbert Pfeiffer, Franz H Grus.   

Abstract

Glaucoma is a chronic neurodegenerative disease and one of the leading causes of blindness. Autoantibody based immune processes are assumed to be involved in its pathogenesis. However, it is still unclear to what extent autoantibody patterns found in the eye (aqueous humor) are congruent to systemic autoantibodies (blood). Consistency would underline the specificity of known serum antibody markers for glaucoma. In this study we used antigen microarrays to analyze autoantibody reactivities in sera and corresponding aqueous humor samples of primary open-angle glaucoma patients (N=37) and non-glaucomatous controls (N=31). Compared to control subjects several divergent immunoreactivities were identified for the glaucoma group in both body fluids. Interestingly, 20% of the tested antigens revealed increased immunoreactivities (e.g., against HSP27, MBP, and α-1-antitrypsin) and 7.5% decreased immunoreactivities (e.g., against GFAP and β-L-crystallin), thus demonstrating a significant alteration of the autoantibody profiles in glaucoma patients. Using an artificial neural network in combination with a unique serum autoantibody pattern on prospective sera we were able to detect glaucoma with a specificity and sensitivity of approximately 93%. The intraindividual comparison revealed a strong correlation of detected immunoreactivities in sera and comparative aqueous humor samples in both study groups. These results emphasize the specificity of immunoreactions found in blood samples of glaucoma patients. Furthermore they indicate the necessity of analyzing not only up-regulated but also down-regulated antibody reactivities, which might be likewise relevant for the understanding of other diseases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21843631     DOI: 10.1016/j.bbi.2011.07.241

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  34 in total

1.  Retinal and Optic Nerve Damage is Associated with Early Glial Responses in an Experimental Autoimmune Glaucoma Model.

Authors:  Rozina Noristani; Sandra Kuehn; Gesa Stute; Sabrina Reinehr; Mathias Stellbogen; H Burkhard Dick; Stephanie C Joachim
Journal:  J Mol Neurosci       Date:  2016-01-08       Impact factor: 3.444

2.  Biomarkers for glaucoma: from the lab to the clinic.

Authors:  N Von Thun Und Hohenstein-Blaul; S Kunst; N Pfeiffer; F H Grus
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

3.  Molecular biomarkers in glaucoma.

Authors:  Sanjoy K Bhattacharya; Richard K Lee; Franz H Grus
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

4.  Lack of immunoglobulins does not prevent C1q binding to RGC and does not alter the progression of experimental glaucoma.

Authors:  Qiong J Ding; Amy C Cook; Alina V Dumitrescu; Markus H Kuehn
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-19       Impact factor: 4.799

Review 5.  A decade of proteomics studies of glaucomatous neurodegeneration.

Authors:  Gülgün Tezel
Journal:  Proteomics Clin Appl       Date:  2014-02-16       Impact factor: 3.494

Review 6.  [Basic biochemical processes in glaucoma progression].

Authors:  N von Thun und Hohenstein-Blaul; S Kunst; N Pfeiffer; F H Grus
Journal:  Ophthalmologe       Date:  2015-05       Impact factor: 1.059

7.  Western blot patterns of serum autoantibodies against optic nerve antigens in dogs with goniodysgenesis-related glaucoma.

Authors:  Stephanie A Pumphrey; Stefano Pizzirani; Christopher G Pirie; M Sawkat Anwer; Tanya Logvinenko
Journal:  Am J Vet Res       Date:  2013-04       Impact factor: 1.156

8.  Immunoproteomic analysis of potential serum biomarker candidates in human glaucoma.

Authors:  Gülgün Tezel; Ivey L Thornton; Melissa G Tong; Cheng Luo; Xiangjun Yang; Jian Cai; David W Powell; Joern B Soltau; Jeffrey M Liebmann; Robert Ritch
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-13       Impact factor: 4.799

9.  Protein Microarrays for Ocular Diseases.

Authors:  Guillermo Solís-Fernández; Ana Montero-Calle; Miren Alonso-Navarro; Miguel Ángel Fernandez-Torres; Victoria Eugenia Lledó; María Garranzo-Asensio; Rodrigo Barderas; Ana Guzman-Aranguez
Journal:  Methods Mol Biol       Date:  2021

Review 10.  A proteomics view of the molecular mechanisms and biomarkers of glaucomatous neurodegeneration.

Authors:  Gülgün Tezel
Journal:  Prog Retin Eye Res       Date:  2013-02-05       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.